PAG
TBPH icon

Private Advisor Group’s Theravance Biopharma TBPH Stock Holding History

Private Advisor Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,036
Closed -$206K – 2839
2025
Q4 		$206K Buy
+11,036
New +$183K ﹤0.01% 2387
2025
Q3 		– Sell
-10,100
Closed -$111K – 2688
2025
Q2 		$111K Buy
+10,100
New +$98.2K ﹤0.01% 2302

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Private Advisor Group's TBPH Position: Q1 2026 in Review

Private Advisor Group sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 11,036 shares — an estimated $206K sold.

Private Advisor Group first reported a position in TBPH in Q2 2025 and held it in 2 quarters. The position peaked at $206K in Q4 2025. 174 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Private Advisor Group reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Private Advisor Group sold 11,036 Theravance Biopharma shares in Q1 2026, an estimated $206K.
  • Private Advisor Group first reported a position in Theravance Biopharma in Q2 2025 and held it in 2 quarters.
  • Private Advisor Group's Theravance Biopharma position peaked at $206K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.